Romain et al. reported that CD2 on T cells was associated with directional migration and that the interaction between CD2 on T cells and CD58 on lymphoma cells accelerated killing and serial killing, and the elevated CD58 expression on pretreatment tumor samples in patients with relapsed or refractory large B cell lymphomas treated with CD19-specific CAR T cell therapy was associated with complete clinical response and survival 45. This evidence concerns the gene CD19 and neoplasm.